MCP Waters-The Science of What's Possible
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on February 1, 2006.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M500239-MCP200v1
5/2/245    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hof, D.
Right arrow Articles by Raats, J. M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hof, D.
Right arrow Articles by Raats, J. M. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on July 29, 2005
Revised on September 22, 2005
Accepted on October 31, 2005

A novel subtractive antibody phage display method to discover disease markers

Daniëlle Hof, Kalok Cheung, Hilde E. Roossien, Ger J. M. Pruijn, and Jos M. H. Raats

Department of Biochemistry NWI 161, Radboud University Nijmegen, Nijmegen NL-6500 HB

Corresponding Author: j.raats{at}ncmls.ru.nl

Today’s research demands fast identification of potential diagnostic and therapeutic targets. We describe a novel phage display strategy to identify disease-related proteins that are specifically expressed in a certain (diseased) tissue or cell. Phages displaying antibody fragments are selected on complex protein mixtures in a two-step manner, combining subtractive selection in solution with further enrichment of specific phages on two-dimensional western blots. Targets recognized by the resulting recombinant antibodies are immunoaffinity purified and identified by mass spectrometry. We used antibody fragment libraries from autoimmune patients to discover apoptosis-specific and disease-related targets. One of the three identified targets is the U1-70K protein, a marker for SLE overlap disease. Interestingly, the epitope on U1-70K, recognized by the selected recombinant antibody, is shown to be apoptosis-dependent, and such epitopes are believed to be involved in breaking tolerance to self-antigens. The other two proteins are identified as PSF / p54nrb and hnRNP C.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Brief Funct Genomic ProteomicHome page
D. Saerens, G. H. Ghassabeh, and S. Muyldermans
Antibody technology in proteomics
Brief Funct Genomic Proteomic, July 1, 2008; 7(4): 275 - 282.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.